What is Dr. Zubair Khalid's research focus?

Dr. Zubair Khalid specializes in molecular virology, mRNA vaccine development, and computational biology, with a focus on avian pathogens like IBDV and Avian Reovirus.

Where is Dr. Zubair Khalid currently working?

Dr. Zubair Khalid is a Postdoctoral Research Associate at the University of Maryland (UMD), specifically within the Department of Animal and Avian Sciences.

FDA-Approved Biologics for Atopic Dermatitis: A Practical Guide

By Dr. Zubair Khalid, DVM, MS, PhD · 2026-08-11

Introduction to FDA-Approved Biologics for Atopic Dermatitis

Atopic dermatitis (AD) is a chronic, relapsing inflammatory skin disease characterized by intense pruritus, eczematous lesions, and skin barrier dysfunction. It affects approximately 10–20% of children and 5–10% of adults in developed countries, with a substantial subset of patients suffering from moderate-to-severe disease that is inadequately controlled by topical therapies. The pathophysiology of AD involves a complex interplay between genetic predisposition, epidermal barrier defects, dysregulation of the innate immune system, and aberrant type 2 T-helper (Th2) cell–mediated inflammation. The Th2 cytokines interleukin-4 (IL-4), IL-13, and IL-31 are central drivers of the disease, promoting immunoglobulin E (IgE) class switching, eosinophil recruitment, and pruritus.

Overview of Atopic Dermatitis

The clinical presentation of AD spans a spectrum from localized flexural eczema to generalized erythroderma. Diagnosis is primarily clinical, based on pruritus, typical morphology and distribution, and chronicity. Disease severity is commonly assessed using validated instruments such as the Eczema Area and Severity Index (EASI), the Investigator's Global Assessment (IGA), and the Dermatology Life Quality Index (DLQI). Moderate-to-severe disease is defined by an EASI score greater than 16 or an IGA score of 3 or higher, often accompanied by significant impact on quality of life.

The molecular pathology of AD is dominated by Th2 polarization. Upon allergen exposure or epithelial damage, keratinocytes release thymic stromal lymphopoietin (TSLP), IL-25, and IL-33, which activate dendritic cells to prime naïve T cells toward a Th2 phenotype. These Th2 cells secrete IL-4, IL-5, IL-13, and IL-31. IL-4 and IL-13 signal through the type 2 IL-4 receptor (IL-4Rα/IL-13Rα1 heterodimer) to activate signal transducer and activator of transcription 6 (STAT6), driving IgE class switching in B cells, upregulating vascular cell adhesion molecule 1 (VCAM-1) on endothelium, and promoting goblet cell hyperplasia. IL-13 also acts directly on keratinocytes to suppress expression of filaggrin and other barrier proteins, exacerbating transepidermal water loss. IL-31, signaling through the IL-31 receptor alpha (IL-31RA) and oncostatin M receptor beta (OSMRβ) complex, is a major mediator of pruritus.

The Role of Biologics in Treatment

Biologics are therapeutic proteins—typically monoclonal antibodies—that selectively target specific immune pathways. For AD, the approved biologics intercept key Th2 cytokines or their receptors, providing targeted immunomodulation with a more favorable safety profile than broad-spectrum systemic immunosuppressants such as cyclosporine or methotrexate. The currently FDA-approved biologics for AD are:

Dupilumab (Dupixent®): a fully human monoclonal antibody against the IL-4 receptor alpha subunit (IL-4Rα), blocking both IL-4 and IL-13 signaling. Approved in 2017 for moderate-to-severe AD in adults, later expanded to adolescents (2019) and children aged 6 months and older (2022).
Tralokinumab (Adbry®): a human monoclonal antibody that binds IL-13, preventing its interaction with IL-13Rα1 and IL-13Rα2. Approved in 2021 for adults, expanded to adolescents (2023).
Lebrikizumab (Ebglyss®): a humanized monoclonal antibody that binds IL-13 with high affinity, blocking IL-13 signaling. Approved in 2024 for adults and adolescents aged 12 years and older.

Additionally, the Janus kinase (JAK) inhibitor baricitinib (Olumiant®) was approved in 2022 for moderate-to-severe AD, though it is a small molecule, not a biologic. This guide focuses on the biologics, but baricitinib is referenced for comparative context where relevant. For a broader historical perspective on biologic approvals across therapeutic areas, see FDA Approved Biologics by Year.

Mechanisms of Action of Approved Biologics

Understanding the precise molecular targets of each biologic is essential for rational prescribing, predicting efficacy, and anticipating adverse effects. The approved biologics for AD target two nodes in the Th2 cascade: the shared IL-4/IL-13 pathway and IL-13 alone.

IL-4/IL-13 Pathway Inhibition

Dupilumab is a fully human immunoglobulin G4 (IgG4) monoclonal antibody that binds specifically to the IL-4Rα subunit. This subunit is a component of both the type 1 IL-4 receptor (IL-4Rα/γc), expressed on hematopoietic cells, and the type 2 IL-4 receptor (IL-4Rα/IL-13Rα1), expressed on non-hematopoietic cells including keratinocytes, fibroblasts, and smooth muscle cells. By occupying IL-4Rα, dupilumab simultaneously blocks:

IL-4 signaling through both receptor types, abrogating STAT6 phosphorylation and downstream Th2 differentiation, IgE class switching, and Th2 cytokine production.
IL-13 signaling through the type 2 receptor, since IL-13 requires IL-4Rα for signal transduction.

This dual blockade is mechanistically distinct from targeting a single cytokine. The functional consequences include reduced IgE levels, decreased expression of Th2-associated chemokines such as CCL17 (TARC) and CCL22 (MDC), and restoration of keratinocyte barrier protein expression. Dupilumab does not deplete cells; it is a receptor antagonist with no antibody-dependent cell-mediated cytotoxicity (ADCC) activity, owing to its IgG4 backbone with a stabilized hinge region.

IL-13-Specific Inhibition

Tralokinumab and lebrikizumab both neutralize IL-13, but they differ in their binding epitopes and pharmacokinetic properties.

Tralokinumab is a fully human IgG4 monoclonal antibody that binds to the D-helix of IL-13, a region critical for interaction with IL-13Rα1 and IL-13Rα2. By sterically hindering IL-13 from engaging its receptors, tralokinumab prevents IL-13-mediated signaling through the type 2 IL-4 receptor complex. Notably, tralokinumab also blocks IL-13 binding to IL-13Rα2, a decoy receptor that may sequester IL-13; the clinical significance of this interaction remains under investigation.

Lebrikizumab is a humanized IgG4 monoclonal antibody that binds to a different epitope on IL-13, specifically the region involved in IL-13Rα1 binding. Lebrikizumab has a higher binding affinity for IL-13 (Kd ≈ 3 pM) compared to tralokinumab (Kd ≈ 30 pM), which may translate to more complete neutralization of IL-13 at lower serum concentrations. However, the clinical relevance of this affinity difference has not been established in head-to-head trials.

Both IL-13-specific antibodies leave IL-4 signaling through the type 1 receptor intact. This is a deliberate design choice: IL-4 is essential for Th2 differentiation and IgE production, but in established AD, IL-13 is the dominant effector cytokine driving keratinocyte dysfunction and skin inflammation. The clinical efficacy of IL-13 blockade alone, while slightly lower than dual IL-4/IL-13 blockade in aggregate analyses, confirms the centrality of IL-13 in AD pathogenesis.

Clinical Efficacy and Key Clinical Trials

The pivotal trials for each biologic established efficacy using co-primary endpoints of IGA 0 or 1 (clear or almost clear) and at least a 75% improvement in EASI (EASI-75) at the end of the induction period, typically 16 weeks. Pruritus reduction, measured by the Peak Pruritus Numerical Rating Scale (NRS), was a key secondary endpoint.

Dupilumab Trials

The SOLO 1 and SOLO 2 trials were phase 3, randomized, double-blind, placebo-controlled studies enrolling 671 and 708 adults with moderate-to-severe AD, respectively. Patients received dupilumab 300 mg subcutaneously every two weeks (after a 600 mg loading dose) or placebo for 16 weeks. In SOLO 1, 37% of dupilumab-treated patients achieved IGA 0/1 versus 10% with placebo; EASI-75 was achieved by 51% versus 15%. SOLO 2 showed similar results: 36% IGA 0/1 and 44% EASI-75 for dupilumab, versus 8% and 12% for placebo. Pruritus NRS improved by a mean of 3.2 points from baseline in dupilumab-treated patients, compared to 1.4 points with placebo.

The CHRONOS trial evaluated dupilumab with concomitant topical corticosteroids (TCS) over 52 weeks. At week 16, 64% of patients receiving dupilumab plus TCS achieved EASI-75, versus 22% with placebo plus TCS. Importantly, the response was sustained at week 52, with 65% of dupilumab-treated patients maintaining EASI-75. The LIBERTY AD PEDS trial in children aged 6–11 years demonstrated an EASI-75 rate of 61% at week 16 with dupilumab plus TCS, versus 20% with placebo plus TCS.

Tralokinumab Trials

The ECZTRA 1 and ECZTRA 2 trials were phase 3, randomized, double-blind, placebo-controlled studies enrolling 802 and 794 adults, respectively. Patients received tralokinumab 300 mg subcutaneously every two weeks (with a 600 mg loading dose) or placebo for 16 weeks. In ECZTRA 1, 25% of tralokinumab-treated patients achieved IGA 0/1 versus 13% with placebo; EASI-75 was achieved by 33% versus 11%. ECZTRA 2 reported IGA 0/1 in 33% versus 12% and EASI-75 in 41% versus 14%. Pruritus NRS improvement of ≥4 points was achieved by 25% of tralokinumab patients in ECZTRA 1 and 30% in ECZTRA 2, versus 12% and 15% with placebo.

The ECZTRA 3 trial assessed tralokinumab with TCS, reporting EASI-75 in 56% of tralokinumab-plus-TCS patients at week 16, versus 37% with placebo plus TCS. Long-term extension data from ECZTRA 1 and 2 showed sustained responses through 52 weeks, with approximately 70% of initial responders maintaining EASI-75.

Lebrikizumab Trials

The ADvocate 1 and ADvocate 2 trials were phase 3, randomized, double-blind, placebo-controlled studies enrolling 424 and 445 adults and adolescents (≥12 years), respectively. Patients received lebrikizumab 250 mg subcutaneously every two weeks (with a 500 mg loading dose at weeks 0 and 2) or placebo for 16 weeks. In ADvocate 1, 33% of lebrikizumab-treated patients achieved IGA 0/1 versus 12% with placebo; EASI-75 was achieved by 52% versus 18%. ADvocate 2 reported IGA 0/1 in 31% versus 15% and EASI-75 in 48% versus 19%. Pruritus NRS improvement of ≥4 points was achieved by 46% of lebrikizumab patients in ADvocate 1 and 41% in ADvocate 2, versus 19% and 21% with placebo.

The ADhere trial evaluated lebrikizumab with TCS, showing EASI-75 in 67% of lebrikizumab-plus-TCS patients at week 16, versus 30% with placebo plus TCS. Notably, lebrikizumab was administered every four weeks after the initial loading phase in the maintenance period, offering a less frequent dosing schedule than the every-two-week regimens of dupilumab and tralokinumab.

The following table summarizes the key efficacy outcomes from the pivotal trials:

Biologic	Trial	IGA 0/1 (Drug vs Placebo)	EASI-75 (Drug vs Placebo)	Pruritus NRS ≥4-point Improvement
Dupilumab	SOLO 1	37% vs 10%	51% vs 15%	41% vs 12%
Dupilumab	SOLO 2	36% vs 8%	44% vs 12%	36% vs 10%
Tralokinumab	ECZTRA 1	25% vs 13%	33% vs 11%	25% vs 12%
Tralokinumab	ECZTRA 2	33% vs 12%	41% vs 14%	30% vs 15%
Lebrikizumab	ADvocate 1	33% vs 12%	52% vs 18%	46% vs 19%
Lebrikizumab	ADvocate 2	31% vs 15%	48% vs 19%	41% vs 21%

These data are derived from the respective phase 3 programs; direct cross-trial comparisons are confounded by differences in patient populations, concomitant medication use, and trial conduct.

Safety Profiles and Adverse Events

The safety profiles of the approved AD biologics are generally favorable, particularly when compared to systemic immunosuppressants. However, class-specific adverse events warrant attention.

Common Adverse Events

Conjunctivitis is the most clinically significant adverse event associated with all three biologics, occurring more frequently than with placebo. The incidence ranges from 5–10% with dupilumab, 5–8% with tralokinumab, and 7–12% with lebrikizumab in clinical trials. The mechanism is not fully elucidated but is hypothesized to involve reduced IL-13 signaling in conjunctival goblet cells, leading to altered mucin production and ocular surface inflammation. Most cases are mild-to-moderate and manageable with artificial tears, topical antihistamines, or short courses of topical corticosteroids. Severe conjunctivitis requiring ophthalmologic referral occurs in less than 1% of patients.

Injection site reactions are reported in 5–15% of patients across trials, manifesting as erythema, swelling, or pain at the injection site. These are typically mild and self-limited, occurring more frequently with the first injections and decreasing with subsequent doses.

Upper respiratory tract infections and nasopharyngitis are reported at slightly higher rates with biologics than placebo, though the absolute difference is small (2–5%). Herpes simplex virus infections, including herpes labialis and eczema herpeticum, occur at a modestly increased frequency, particularly with dupilumab.

Serious Adverse Events and Monitoring

Serious adverse events are rare. Anaphylaxis has been reported with all three biologics, though the incidence is less than 0.1%. Patients should be counseled on signs of hypersensitivity reactions. Eosinophilia, sometimes transient and asymptomatic, has been observed with dupilumab; in rare cases, it has been associated with eosinophilic conditions such as eosinophilic pneumonia or vasculitis, though a causal relationship has not been firmly established.

Long-term safety data from open-label extension studies (up to 3–5 years) have not revealed new safety signals. There is no evidence of increased risk of malignancy or serious infections with any of the three biologics. Unlike JAK inhibitors such as baricitinib, which carry boxed warnings for thrombosis, major adverse cardiovascular events, and malignancy, the biologics do not require routine laboratory monitoring. However, baseline assessment for latent tuberculosis and hepatitis B is recommended before initiating any biologic therapy, consistent with standard practice for immunomodulatory agents.

For a comprehensive overview of the regulatory framework governing post-approval safety monitoring and manufacturing changes, see FDA Post Approval Changes Guidance Biologics.

Comparative Analysis and Positioning in Treatment Paradigm

The choice among dupilumab, tralokinumab, and lebrikizumab—or between biologics and JAK inhibitors—requires consideration of efficacy, safety, dosing convenience, and patient-specific factors.

Head-to-Head Comparisons

No head-to-head trials have directly compared the three biologics. Indirect comparisons using network meta-analyses suggest that dupilumab may have a slight efficacy advantage over tralokinumab and lebrikizumab for EASI-75 at week 16, but the differences are modest and within the confidence intervals of cross-trial variability. Dupilumab's dual IL-4/IL-13 blockade theoretically provides broader suppression of the Th2 axis, which may explain its marginally higher response rates. However, IL-13-specific agents may be preferable in patients who experience conjunctivitis, as some evidence suggests a lower incidence with tralokinumab.

Lebrikizumab offers the advantage of every-four-week maintenance dosing after the initial loading phase, which may improve adherence. Tralokinumab has the most extensive long-term safety data in the IL-13 class, with 52-week and 3-year extension data published.

Place in Therapy

The current treatment paradigm positions biologics as second-line therapy for patients with moderate-to-severe AD who have failed topical corticosteroids and/or topical calcineurin inhibitors. The 2023 American Academy of Dermatology guidelines recommend dupilumab as the first-line biologic, given its longer track record, established pediatric indications, and robust efficacy data. Tralokinumab and lebrikizumab are appropriate alternatives, particularly in patients who prefer a more targeted IL-13 approach or who have contraindications to dupilumab.

JAK inhibitors (baricitinib, upadacitinib, abrocitinib) offer faster onset of action and oral administration but carry more extensive safety warnings, including dose-dependent risks of infection, thrombosis, and cardiovascular events. They are generally reserved for patients who have failed or are intolerant to biologics, or who require rapid symptom control. The choice between a biologic and a JAK inhibitor should be individualized, weighing efficacy, safety, and patient preference.

Biologics are also being positioned earlier in the treatment algorithm for pediatric patients, given the safety concerns of long-term systemic immunosuppressants in children. Dupilumab is approved for children as young as 6 months, and tralokinumab for adolescents aged 12 years and older.

Biosimilars and Market Considerations

The high cost of biologic therapies—annual wholesale acquisition costs exceeding $40,000—has driven interest in biosimilars. However, the AD biologic market is still in its early stages of biosimilar development.

Biosimilar Landscape

Dupilumab's patent protection extends to the mid-2030s in the United States, and no biosimilars are currently in late-stage development. Tralokinumab and lebrikizumab are similarly protected. The absence of biosimilar competition means that the market remains dominated by originator products, with pricing determined by manufacturer-set list prices and negotiated rebates.

The development of biosimilars for AD biologics faces several technical challenges. Monoclonal antibodies are large, glycosylated proteins produced in mammalian cell lines (typically Chinese hamster ovary cells). The manufacturing process—including cell line development, upstream culture conditions, downstream purification, and formulation—must be replicated to produce a product that is highly similar to the originator. Even minor differences in glycosylation patterns can affect Fc receptor binding, ADCC activity, and pharmacokinetics. The regulatory pathway requires extensive analytical characterization, comparative pharmacokinetic studies, and clinical immunogenicity assessments.

Regulatory Pathway for Biosimilars

The Biologics Price Competition and Innovation Act (BPCIA) of 2009 established an abbreviated licensure pathway for biosimilars under 42 U.S.C. § 262(k). A biosimilar must demonstrate that it is "highly similar" to the reference product notwithstanding minor differences in clinically inactive components, and that there are no clinically meaningful differences in safety, purity, and potency. The approval pathway involves:

Analytical similarity assessment, including primary structure, higher-order structure, post-translational modifications, and biological activity.
Nonclinical studies, including pharmacokinetic and toxicological evaluations in animal models.
Clinical pharmacokinetic and, if necessary, pharmacodynamic studies to demonstrate equivalence.
Immunogenicity assessment, typically through a comparative clinical trial.

For a deeper understanding of the regulatory requirements, see Biologics License Application FDA and FDA Approval Process for Biologics.

The market implications of biosimilar entry are substantial. In the United States, biosimilars typically launch at a 15–30% discount to the reference product, with prices declining further as multiple biosimilars enter the market. For AD, the eventual arrival of biosimilars is expected to improve patient access and reduce healthcare costs, but this is unlikely before the mid-2030s.

Practical Considerations for Industry Scientists

For scientists in bioprocessing and formulation development, the AD biologics present specific technical challenges and opportunities.

Manufacturing Challenges

All three approved biologics are IgG4 monoclonal antibodies produced in Chinese hamster ovary (CHO) cell lines. The manufacturing process typically involves:

Upstream processing: Fed-batch or perfusion cell culture in stirred-tank bioreactors. CHO cells are cultured in chemically defined media at 37°C, pH 7.0–7.2, with dissolved oxygen maintained at 30–50% saturation. Fed-batch cultures typically run for 12–14 days, achieving viable cell densities of 10–20 × 10⁶ cells/mL and product titers of 2–5 g/L.

Downstream processing: Protein A affinity chromatography for capture, followed by low-pH viral inactivation (pH 3.5–3.8 for 30–60 minutes), two polishing chromatography steps (typically cation exchange and anion exchange), and viral filtration (20 nm nanofiltration). The final product is formulated via ultrafiltration/diafiltration into the desired buffer.

Formulation: The final drug product is typically formulated at a concentration of 150–300 mg/mL in a histidine or citrate buffer (pH 5.5–6.5), with sucrose or trehalose as a stabilizer and polysorbate 80 as a surfactant. High-concentration formulations (≥200 mg/mL) are required to deliver therapeutic doses (300 mg) in a single 1–2 mL subcutaneous injection, which presents challenges for viscosity and protein aggregation.

The IgG4 backbone is chosen for its reduced Fc-mediated effector functions, which minimizes the risk of ADCC and complement-dependent cytotoxicity. However, IgG4 antibodies can undergo Fab-arm exchange in vivo, leading to bispecific antibodies with reduced avidity. To prevent this, the AD biologics have been engineered with a stabilizing mutation in the hinge region (e.g., the S228P mutation in dupilumab), which prevents Fab-arm exchange while maintaining the reduced effector function profile.

Formulation and Delivery Systems

The delivery systems for AD biologics have evolved to improve patient convenience. Dupilumab is available in both pre-filled syringes and an autoinjector device (Dupixent Pen). Tralokinumab is supplied as a pre-filled syringe, and lebrikizumab is available in both pre-filled syringes and an autoinjector. These devices are designed for self-administration after appropriate training, with needle safety features to prevent needlestick injuries.

Formulation stability is a critical consideration. Monoclonal antibodies are susceptible to aggregation, oxidation, deamidation, and fragmentation during storage. The formulation must maintain protein stability over a shelf life of 24–36 months at 2–8°C. Key stability-indicating parameters include:

Soluble aggregates (measured by size-exclusion chromatography): should be <5% of total protein.
Subvisible particles (measured by micro-flow imaging or light obscuration): should be <10,000 particles/mL for particles ≥10 μm.
Charge variants (measured by ion-exchange chromatography): acidic and basic variants should be within specified ranges.
Potency (measured by cell-based bioassay): should be within 80–125% of the reference standard.

For industry scientists involved in biosimilar development, the analytical similarity assessment requires state-of-the-art techniques including mass spectrometry for primary structure confirmation, hydrogen-deuterium exchange for higher-order structure comparison, and surface plasmon resonance for binding kinetics. The regulatory expectations are detailed in the FDA's guidance on biosimilar development, which emphasizes a stepwise approach beginning with extensive analytical characterization. For an overview of the development process, see Biologics Development.

Common Pitfalls and Misconceptions

Several misconceptions and pitfalls are common among clinicians and industry scientists when working with AD biologics.

Misinterpreting Efficacy Data

Pitfall 1: Comparing across trials without adjusting for baseline differences. The pivotal trials for dupilumab, tralokinumab, and lebrikizumab enrolled different patient populations with varying baseline disease severity, prior treatment history, and concomitant medication use. Direct cross-trial comparisons of response rates are statistically invalid. Network meta-analyses that adjust for these differences are more reliable but still subject to assumptions.

Pitfall 2: Equating EASI-75 with disease clearance. EASI-75 represents a 75% improvement from baseline, not clearance. A patient with a baseline EASI of 30 who achieves EASI-75 still has an EASI of 7.5, which is moderate disease. Clinicians should assess absolute EASI scores and patient-reported outcomes, not just percentage improvement.

Pitfall 3: Ignoring the time course of response. The onset of action for biologics is gradual. In the pivotal trials, the separation from placebo began at 2–4 weeks, but maximal responses were not achieved until 12–16 weeks. Premature discontinuation due to perceived lack of efficacy at 4–8 weeks is a common clinical error.

Overlooking Safety Signals

Pitfall 4: Dismissing conjunctivitis as a minor adverse event. While most cases are mild, conjunctivitis can be persistent and bothersome, leading to treatment discontinuation in some patients. Proactive monitoring and early intervention with artificial tears or topical anti-inflammatory agents can mitigate this issue.

Pitfall 5: Assuming all biologics have identical safety profiles. While the class effects are similar, subtle differences exist. For example, the incidence of injection site reactions may be lower with tralokinumab, and the rate of conjunctivitis may differ among agents. These differences, while small, may influence treatment choice in individual patients.

Pitfall 6: Failing to screen for latent infections. Although the risk of reactivation is low, all patients should be screened for tuberculosis and hepatitis B before initiating biologic therapy. This is a standard precaution that is sometimes overlooked in busy clinical practice.

Future Directions and Emerging Biologics

The AD treatment landscape is evolving rapidly, with several novel agents in late-stage development.

Novel Targets

OX40/OX40L inhibitors are among the most promising emerging therapies. OX40 (CD134) is a costimulatory receptor expressed on activated T cells, and its ligand OX40L is expressed on antigen-presenting cells. Blocking OX40-OX40L interaction prevents T-cell activation and differentiation, potentially providing broader immunomodulation than cytokine-specific blockade. Rocatinlimab (an anti-OX40 antibody) and amlitelimab (an anti-OX40L antibody) have shown promising phase 2 results, with significant improvements in EASI-75 compared to placebo. Phase 3 trials are ongoing.

IL-31 receptor antagonists target the pruritus pathway more directly. Nemolizumab, an anti-IL-31RA antibody, has demonstrated rapid and substantial reductions in pruritus, with moderate improvements in skin inflammation. It is currently under FDA review for AD and may be approved in the near future.

TSLP inhibitors such as tezepelumab, already approved for severe asthma, are being investigated for AD. TSLP is an epithelial-derived cytokine that initiates the Th2 cascade, and its blockade may provide upstream suppression of inflammation.

Combination Therapies

Combination strategies are being explored to enhance efficacy. The rationale is that different biologics target complementary pathways: for example, combining an IL-4/IL-13 blocker with an IL-31 blocker could address both inflammation and pruritus more completely. However, the safety and efficacy of such combinations have not been established, and the cost implications are substantial.

The development of oral small-molecule JAK inhibitors continues to expand, with upadacitinib and abrocitinib showing high efficacy with rapid onset. The long-term safety profile of these agents, particularly regarding cardiovascular and thromboembolic risks, will determine their ultimate role in the treatment algorithm.

Frequently Asked Questions

What are the FDA-approved biologics for atopic dermatitis?

The FDA-approved biologics for atopic dermatitis are dupilumab (Dupixent®), tralokinumab (Adbry®), and lebrikizumab (Ebglyss®). Dupilumab targets the IL-4 receptor alpha subunit, blocking both IL-4 and IL-13 signaling. Tralokinumab and lebrikizumab both neutralize IL-13 directly. The JAK inhibitor baricitinib (Olumiant®) is also approved for moderate-to-severe AD but is a small molecule, not a biologic.

How do biologics for atopic dermatitis work?

Biologics for AD are monoclonal antibodies that selectively neutralize key cytokines in the type 2 inflammatory pathway. Dupilumab blocks the shared IL-4 receptor, inhibiting both IL-4 and IL-13 signaling. Tralokinumab and lebrikizumab bind to IL-13 and prevent it from engaging its receptors. By interrupting these cytokine signals, biologics reduce Th2-mediated inflammation, restore skin barrier function, and alleviate pruritus.

What is the difference between dupilumab and tralokinumab?

The primary difference is the target: dupilumab blocks the IL-4 receptor alpha subunit, inhibiting both IL-4 and IL-13 signaling, while tralokinumab binds IL-13 directly, leaving IL-4 signaling intact. In clinical trials, dupilumab has shown slightly higher efficacy rates, but tralokinumab may be associated with a lower incidence of conjunctivitis. Both are administered subcutaneously every two weeks after a loading dose.

Are biologics for atopic dermatitis safe?

Yes, biologics for AD have a favorable safety profile compared to systemic immunosuppressants. The most common adverse events are conjunctivitis, injection site reactions, and upper respiratory tract infections. Serious adverse events, including anaphylaxis, are rare. Unlike JAK inhibitors, biologics do not carry boxed warnings for thrombosis or malignancy and do not require routine laboratory monitoring.

How effective are biologics for atopic dermatitis?

In pivotal trials, approximately 30–50% of patients achieved EASI-75 (75% improvement in the Eczema Area and Severity Index) after 16 weeks of treatment, compared to 10–20% with placebo. Responses are sustained with continued treatment, and many patients achieve clear or almost clear skin (IGA 0/1). Efficacy varies among individuals, and some patients may require additional time or dose adjustments to achieve optimal response.

Can biologics be used in children with atopic dermatitis?

Yes. Dupilumab is approved for children as young as 6 months with moderate-to-severe AD. Tralokinumab is approved for adolescents aged 12 years and older, and lebrikizumab is approved for adults and adolescents aged 12 years and older. Pediatric dosing is weight-based, and clinical trials have demonstrated efficacy and safety in these populations.

What is the cost of biologics for atopic dermatitis?

The annual wholesale acquisition cost for AD biologics is approximately $40,000–$50,000. Actual out-of-pocket costs vary depending on insurance coverage, copay assistance programs, and manufacturer discounts. Biosimilars, which could reduce costs, are not expected to enter the market until the mid-2030s due to patent protection.

How are biologics for atopic dermatitis administered?

All three approved biologics are administered by subcutaneous injection. The typical regimen involves a loading dose followed by maintenance dosing every two weeks (dupilumab, tralokinumab) or every four weeks (lebrikizumab). They are available as pre-filled syringes or autoinjector devices for self-administration after appropriate training.

Key Takeaways

Dupilumab, tralokinumab, and lebrikizumab are the three FDA-approved biologics for atopic dermatitis, each targeting the IL-4/IL-13 axis with distinct mechanisms.
Dupilumab blocks both IL-4 and IL-13 signaling via IL-4Rα; tralokinumab and lebrikizumab neutralize IL-13 alone, with lebrikizumab offering every-four-week maintenance dosing.
Pivotal trials demonstrate EASI-75 response rates of 33–52% at week 16, with sustained responses on long-term treatment.
The safety profiles are favorable, with conjunctivitis being the most clinically significant adverse event; no routine laboratory monitoring is required.
Biologics are positioned as second-line therapy for moderate-to-severe AD after topical treatment failure, with dupilumab as the current first-line biologic.
Biosimilar development is in early stages, with market entry expected no earlier than the mid-2030s.
Emerging therapies targeting OX40, IL-31, and TSLP may expand the treatment armamentarium and shift the therapeutic paradigm in the coming years.